Literature DB >> 7916527

Intermittent medication--an alternative?

W Gaebel1.   

Abstract

Neuroleptic maintenance medication is clearly effective for relapse prevention in schizophrenia. However, besides benefits for the majority of patients, there are also failures and/or serious risks for some patients (e.g., tardive dyskinesia). Since the risk-benefit ratio is often difficult to predict in the individual case, this has stimulated the search for modifications and alternatives to maintenance treatment. In particular, neuroleptic low-dose treatment strategies obviously compare quite favourably with standard-dose treatment concerning relapse prevention and side effects. Alternatively, on the basis of reports on prodromal symptoms preceding a relapse, early intervention, intermittent neuroleptic treatment strategies have been developed. However, all recently completed controlled 2-year studies have not confirmed this strategy to be as effective as maintenance treatment in preventing relapse, although total drug exposure is significantly reduced and social adjustment seems to be unaffected. Therefore, for the majority of patients, intermittent treatment cannot be recommended.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916527     DOI: 10.1111/j.1600-0447.1994.tb05863.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  3 in total

Review 1.  Antipsychotic dosing: how much but also how often?

Authors:  Gary Remington; Shitij Kapur
Journal:  Schizophr Bull       Date:  2010-07-21       Impact factor: 9.306

2.  Plasma levels and estimated dopamine D2 receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study.

Authors:  Saeko Ikai; Takefumi Suzuki; Masaru Mimura; Hiroyuki Uchida
Journal:  Psychopharmacology (Berl)       Date:  2016-09-08       Impact factor: 4.530

Review 3.  The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.

Authors:  Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.